Evidence map›Paper›PMID 38181810›Full record

ReviewThe Lancet. Oncology2024

PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.

Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, Martin J van den Bent, Susan M Chang, Francesco Cicone, John de Groot, Eng-Siew Koh, Ian Law, Emilie Le Rhun and 14 more

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06480721 (FET-PET-Guided Management of Pseudoprogression in Glioblastoma), which is not on this map. Cited by 109 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 4 pooled it
56.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06480721 nanot yet recruitingnot on this map

FET-PET-Guided Management of Pseudoprogression in Glioblastoma

TypeinterventionalSponsorVeerle RuijtersRan2024 to 2027Enrolled144ConditionsGlioblastoma, Radionecrosis of BrainArmsClinical management based on the index MRI and an additional [¹⁸F] FET PET scan
3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 4 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Rhinocerebral mucormycosis: a potential source of false-positive uptake on [European journal of nuclear medicine and molecular imaging · 2026
    Article
  6. Review
  7. Accelerating discovery: Transformative clinical trial models in neuro-oncology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026
    Review
  14. Article
  15. Near complete response recurrent glioblastoma after treatment with [European journal of nuclear medicine and molecular imaging · 2026
    Article
  16. Article
  17. Review
  18. [Neuroradiology · 2026
    Article
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 10 countries.

Nathalie L AlbertDepartment of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany.
Norbert GalldiksDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany; Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Martin J van den BentThe Brain Tumour Center at the Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Susan M ChangDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Francesco CiconeNuclear Medicine Unit, Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy.
John de GrootDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Eng-Siew KohDepartment of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centre, Liverpool, NSW, Australia; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia.
Ian LawDepartment of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark.
Emilie Le RhunDepartment of Neurosurgery, University Hospital Zurich, Zurich, Switzerland; Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Maximilian J MairDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Giuseppe MinnitiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy; IRCCS Neuromed, Pozzilli IS, Italy.
Roberta RudàDivision of Neuro-Oncology, Department of Neuroscience, University of Turin and City of Health and Science of Turin, Turin, Italy.
Andrew M ScottDepartment of Molecular Imaging and Therapy, Austin Health and University of Melbourne, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Susan C ShortLeeds Institute of Medical Research at St James's, The University of Leeds, Leeds, UK.
Marion SmitsDepartment of Radiology & Nuclear Medicine, Erasmus MC-University Medical Centre Rotterdam, Rotterdam, Netherlands; Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Medical Delta, Delft, Netherlands.
Bogdana SuchorskaDepartment of Neurosurgery, Heidelberg University Hospital, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
Nelleke TolboomDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
Tatjana Traub-WeidingerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Joerg-Christian TonnDepartment of Neurosurgery, LMU Hospital, LMU Munich, Munich, Germany.
Antoine VergerDepartment of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Universitè de Lorraine, Nancy, France.
Michael WellerDepartment of Neurology, University Hospital Zurich, Zurich, Switzerland; Department of Neurology, University of Zurich, Zurich, Switzerland.
Patrick Y WenCenter For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Matthias PreusserDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: matthias.preusser@meduniwien.ac.at.
Medical University of Vienna · ATLMU Klinikum · DEUniversity of California, San Francisco · USErasmus MC · NLErasmus MC Cancer Institute · NLForschungszentrum Jülich · DEHarvard University · USHeidelberg University · DEInserm · FRLiverpool Hospital · AUMagna Graecia University · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITPoliclinico Umberto I · ITRigshospitalet · DKThe University of Melbourne · AUUniversity Hospital of Zurich · CHUniversity Medical Center Utrecht · NLUniversity of California, Los Angeles · USUniversity of Leeds · GBUniversity of Zurich · CH

Funding

Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomasR21CA223757 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M. · 2018 to 2019
$366k
NCI NIH HHS R01 CA270027NCI NIH HHS R01 CA279984NCI NIH HHS R21 CA223757
6 · The paper itself

Abstract

Response Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse gliomas has not been established. Therefore, in this Policy Review, we propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas as defined in the 2021 WHO classification of tumours of the central nervous system. These proposed PET RANO criteria provide a conceptual framework that facilitates the structured implementation of PET imaging into clinical research and, ultimately, clinical routine. To this end, the PET RANO 1.0 criteria are intended to encourage specific investigations of amino acid PET imaging of gliomas.

Indexed as

GliomaNeurologyAmino AcidsHumansInternal MedicinePositron-Emission TomographyTranscription FactorsAmino AcidsTranscription Factors

Identifiers

PMID38181810
PMCPMC11787868
OpenAlexW4390490770

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.